20177-59-7

Upstream product

• 2101-88-4 1-azido-4-bromobenzene 
• 471-25-0 Propiolic acid 
• 1423701-54-5 C₁₄H₁₈BrN₃O₂Si 
• 106-40-1 4-bromo-aniline 
• 5467-74-3 4-Bromophenylboronic acid 

Downstream Products

• 1396007-58-1 1-{4'-[5-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,3]triazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid 
• 1423701-70-5 [3-(4-bromo-phenyl)-3H-[1,2,3]triazol-4-yl]-carbamic acid (R)-1-phenyl-ethyl ester 
• 1423689-99-9 C₂₈H₂₅ClN₄O₄ 
• 1423684-56-3 C₂₇H₂₃ClN₄O₄ 
• 1423690-02-1 C₂₇H₂₂ClN₄O₄^(1-)*Na⁽¹⁺⁾ 
• 1423701-59-0 C₁₇H₁₄BrClN₄O₂ 

Relevant academic research and scientific papers

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis

Synthesis and mesomorphic properties of novel [1,2,3]-triazole mesogenic based compounds

A series of five-membered heterocyclic 1,2,3-triazole derivatives with different substituents in N1 position was synthesized. The heterocyclic moiety was connected through an ester function to a p-decyloxyphenyl or p-decyloxybiphenyl tails Polarized micro

Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts

Lysophosphatidic acid is a class of bioactive phospholipid that mediates most of its biological effects through LPA receptors, of which six isoforms have been identified. The recent results from LPA1 knockout mice suggested that blocking LPA1 signaling could provide a potential novel approach for the treatment of idiopathic pulmonary fibrosis. Here, we report the design and synthesis of pyrazole- and triazole-derived carbamates as LPA1-selective and LPA1/3 dual antagonists. In particular, compound 2, the most selective LPA1 antagonist reported, inhibited proliferation and contraction of normal human lung fibroblasts (NHLF) following LPA stimulation. Oral dosing of compound 2 to mice resulted in a dose-dependent reduction of plasma histamine levels in a murine LPA challenge model. Furthermore, we applied our novel antagonists as chemistry probes and investigated the contribution of LPA1/2/3 in mediating the pro-fibrotic responses. Our results suggest LPA1 as the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF.